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Abstract
Background: Repeat cytology and HPV testing is used in triage of women with minor cytological lesions. The
objective of this study was to evaluate 14-type HPV DNA and 5-type HPV mRNA testing in delayed triage of women
with ASC-US/LSIL.
Methods: We compared a DNA test (Roche Cobas 4800) and an 5-type mRNA test (PreTect HPV-Proofer). In total
564 women were included in the study.
Results: The sensitivity among solved cases for CIN3+ were 100 % (15/15) for both tests. The sensitivity for CIN2+
of the HPV DNA test was 100 % (38/38) relative to 79 % (30/38) for the 5-type HPV mRNA test. The corresponding
estimates of specificity for CIN2+ among solved cases were 84 % (393/466; 95 % CI: 81–88) and 91 % (451/498;
95 % CI: 88–93). The positive predictive values for CIN3+ were 13.5 % (15/111) for DNA+ and 19.5 % (15/77) for
5-type mRNA+. Significantly more women screened with 5-type mRNA than DNA returned to screening (81 % vs
71 %, p < 0.01). Subsequently, significantly fewer women were referred for colposcopy/biopsies/treatment (19 %
(105/564) vs 29 % (165/564), p < 0.01).
Conclusions: 5-type HPV mRNA is more specific than 14-type HPV DNA in delayed triage of women with ASC-US/LSIL.
The referral rate for colposcopy was 57 % higher for DNA+ relative to mRNA+ cases (165 vs 105), with the same detection
rate of CIN3+, but the 5-type mRNA test had lower sensitivity for CIN2+. It is important to consider the trade-off between
sensitivity and specificity of the diagnostic test when designing screening algorithms.
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Background
Cervical cancer is the third most common cancer in
women worldwide [1]. Persistent infection of human
papillomavirus (HPV) causes virtually all cases of cer-
vical cancer [2]. In Europe most cervical cancer cases
are caused by HPV types 16, 18, 31, 33, and 45 [1, 3].
Cervical cancer can be prevented by early detection and
treatment of precancerous lesions [4]. Women with
minor cytological cervical lesions have an increased risk
of having, or developing, high-grade dysplasia compared
to women with normal cytology. However, most minor
cytological lesions regress spontaneously, and therefore
careful triage is crucial in order to avoid unnecessary
referrals and overtreatment [5]. In Norway, HPV test is
used in delayed triage of women with atypical squamous
cells of undetermined significance (ASC-US) or low-grade
squamous intraepithelial lesions (LSIL) [6]. If the HPV test
is positive, the woman is referred to colposcopy.
The HPV E6/E7 mRNA test PreTect HPV-Proofer
which detects HPV E6/E7 mRNA from the five most
prevalent types causing cervical cancer has been shown to
have a higher clinical specificity and positive predictive
value (PPV) than HPV DNA tests [7–14]. A high specifi-
city and a low positivity rate of a triage test indicates a low
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referral rate for colposcopy [8]. In this study we performed
a direct comparison of a 5-type HPV mRNA and a 14-
type HPV DNA test in delayed triage of ASC-US/LSIL re-
lated to referral rates for colposcopy, biopsy rates, and
histological outcomes.
Methods
Organized cervical cancer screening was introduced in
Norway in 1995 with the recommendation that all
women 25 to 69 years have a Pap smear collected every
third year [15]. During the study period the Norwegian
cervical cancer program recommended delayed triage
with repeat cytology and HPV testing 6–12 months after
the index diagnosis of ASC-US/LSIL. Women with high-
grade squamous intraepithelial lesions (HSIL) or re-
peated ASC-US/LSIL with a positive HPV test were
referred to colposcopy/biopsy immediately after triage.
Women with a normal smear and a positive HPV test
were recommended a repeat HPV test within 12 months,
whereas women with an ASC-US/LSIL/normal smear
with a negative HPV test were returned to the screening
program at a three-year interval [9].
This study compared test performance of the HPV
mRNA test PreTect HPV-Proofer (PreTect AS, Norway),
which detects E6/E7 mRNA of 5 HPV types, and the HPV
DNA test Cobas 4800 (Roche Molecular Diagnostics),
which detects 14 HPV types. We followed the manufac-
turer’s instructions in preparation of aliquots and detection
of mRNA, while we analyzed HPV DNA in accordance
with national guidelines [10]. The conventional cytology
Fig. 1 Selection of study population
Fig. 2 Screening algorithm for HPV triage
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(Pap smear) consists of sampling cells from the cervical
area. The sample is obtained using a brush, and the cells
are placed directly onto a glass slide and spray fixed. Then
the same brush is placed into a liquid medium (ThinPrep,
Cytyc Corporation, Marlborough, USA) for HPV testing.
In Norway, many hospitals have switched from conven-
tional Pap smears to liquid-based cytology (LBC), but
Ålesund Hospital still uses conventional Pap smears.
The Department of Pathology, Ålesund Hospital, lo-
cated on the western coast of Norway, serves a back-
ground population of approximately 50 000 women at
screening age 25–69 years and assesses 12 000 cervical
smears annually. Since 1999 the department has used
the clinical database SymPathy for administration of
cytological and histological specimens. From January 1,
2001, through September 15, 2014, we identified 47 926
women with 160 466 valid smears, among which 1 577
women had a diagnosis of ASC-US/LSIL after June 30,
2010. Our study commenced on January 4, 2012, when
the department introduced the HPV DNA test. After ex-
cluding women with a history of HSIL, or biopsy with
cervical intraepitelial neoplasi grade 1 or worse (CIN1+),
those under 25 or over 69 years of age, and cases with
none or only one HPV test, 695 women were eligible for
study participation (Fig. 1).
The Norwegian cervical cancer screening program
recommended triage 6 to 12 months after the index
ASC-US/LSIL [6, 9] (Fig. 2). We expanded the triage
follow-up window from 90 to 540 days after the index
smear. Therefore women having triage <90 days (n = 14)
or >540 days (n = 12) after index smear, and women
having direct biopsy (reflex testing) before or at triage
(n = 70), and women who had HSIL at triage (n = 35)
were excluded, leaving 564 women for final analyses.
Either a positive HPV DNA or a positive HPV mRNA
test triggered colposcopy.
We defined solved cases as subjects who returned to the
screening program from either a valid smear/negative HPV
test, or having had a biopsy, which determined future
follow-up/treatment. Corresponding dates were “outcome”
dates for solved cases, while we censored cases not met for
biopsy or incomplete follow-up at last day of study,
September 15, 2014. Abnormal cervical cytology was classi-
fied using the Bethesda system. Cervical biopsies were re-
ported using WHO histological classification of tumors of
the uterine cervix (http://screening.iarc.fr/colpochap.php?-
chap=2). All biopsies were reviewed by one experienced
pathologist (BW). Biopsies with uncertain cellular changes
were immunostained with p16 (INK4a) (Roche mtm la-
boratories AG). If there was a discrepancy between biopsy
and treatment histology, the most severe histology was
endpoint.
The sensitivity of the HPV tests is defined as the pro-
portion of high-grade dysplasia (CIN2+) detected by the
two different HPV tests. In the calculations of specificity,
it is assumed that HPV negative samples without de-
tected dysplasia during the follow-up period were
disease-free.
All analyses were done in SPSS, version 22.0, with
Chi-square test for categorical variables, t-test for con-
tinuous variables, and survival analyses for clinically
solved cases. Significance level was set to p < 0.05.
Results
At index cytology 84 % (473/564) were ASC-US and
16 % (91/564) LSIL. At the most recent screen prior to
index cytology 79 % (444/564) of the women had a nor-
mal cytology within the screening interval, 4 % (24/564)
had a normal cytology beyond the screening interval,
whereas index cytology represented the first smear, ever,
Table 1 Outcome of triage by HPV test (n = 564)
DNA 5-type-mRNA
N = 564 % (95 % CI) N = 564 % (95 % CI)
Back to screening 399 70.7 (66.9–74.5) 459 81.4 (78.2–84.6)*
Met for biopsy 105 18.6 (15.4–21.8) 77 13.7 (10.9–16.5)
Scheduled, not met for biopsy 36 6.4 (4.4–8.4) 15 2.7 (1.4–4.0)*
Incomplete follow-up 24 4.3 (2.6–6.0) 13 2.3 (1.1–3.5)
*p < 0.05
Triage repeat cytology and HPV test 3–18 months after index ASC-US/LSIL cytology
DNA HPV DNA test (Cobas 4800)
5-type-mRNA HPV mRNA test (PreTect HPV-Proofer)
Table 2 Most severe histology from biopsy/cone specimen by
HPV test
Histology HPV DNA 5-type-mRNA
N = 105 % (95 % CI) N = 77 % (95 % CI)
Normal/CIN1 67 63.8 (54.6–73.0) 47 61.0 (50.1–71.9)
CIN2 23 21.9 (14.0–29.8) 15 19.5 (10.7–28.3)
CIN3+ 15 14.3 (7.6–21.0) 15 19.5 (10.7–28.3)
CIN cervical intraepitelial neoplasi
HPV DNA HPV DNA test (Cobas 4800)
5-type-mRNA HPV mRNA test (PreTect HPV-Proofer)
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for 17 % (96/564) of the women. The mean age was
39 years (SD 10.5 years) and nearly 40 % (217/564) of
the women were 25–34 years of age.
Mainly from triage, but also after follow-up of a nor-
mal cytology with a positive HPV test at triage, the 5-
type mRNA test scheduled significantly more women
back to screening, 81 % (459/564), than the DNA test,
71 % (399/564) (p < 0.01). There was no difference in
incomplete follow-ups by screening test, HPV DNA test
4 % (24/564)/mRNA test 2 % (13/564) (p = 0.09). Ac-
cordingly, the DNA test targeted significantly more
women for biopsy, 25 % (141/564) than the 5-type
mRNA test, 16 % (92/564) (p < 0.01) (Table 1). In total
141 women were recommended colposcopy by the
DNA test, and 105 (74 %) met for biopsy. Out of the 92
women scheduled for biopsy by the 5-type mRNA test,
77 (84 %) made a visit (p = 0.12).
There was no difference in histology outcome by
screening test among women who had biopsy and/or
treatment. Both tests identified 14 women with CIN3
and one woman with squamous cell carcinoma (Table 2).
The positive predictive value (PPV) for CIN2+ was 34 %
(38/111) for HPV DNA and 39 % (30/77) for the 5-type
mRNA test. The PPVs for CIN3+ were 13.5 % (15/111)
and 19.5 % (15/77) for the DNA and the 5-type mRNA
test (Table 3). The increased referral rate to biopsy among
DNA-tested women relative to mRNA-tested women re-
sulted in 10 more cases of normal histology, 10 more
cases of CIN1, and eight more cases of CIN2 (Table 4).
At triage, 65 % (386/564) were negative in both tests
(DNA-/mRNA-), while 29 % (165/564) and 19 % (105/
564) were positive with the DNA or 5-type mRNA test,
respectively. In total, 98 women were double positive
(DNA+/mRNA+). Among the 73 HPV DNA positive
and 5-type mRNA negative women (DNA+/mRNA-), 69
were positive for HPV types other than 16 and 18, two
for HPV16, and two for HPV18. Among women with a
negative HPV DNA test, seven tests were positive with
the 5-type mRNA test (DNA-/mRNA+), four HPV16
and three HPV other than 16 and 18. Among the 53
women testing positive for HPV16 (DNA+ and/or
mRNA+), 44 tested positive in both tests (DNA
+/mRNA+), 48 tested positive for HPV DNA, and 49
for 5-type mRNA. Similar results for HPV18, 11
women out of 14 were double positive (DNA+/mRNA
+), 13 tested positive for HPV DNA, while 12 tested
positive for 5-type mRNA. The largest difference was
for HPV other types than HPV16 and HPV18. Only
39 out of 116 tested positive in both tests (DNA
+/mRNA+), 110 tested positive for DNA, and 44
tested positive for 5-type mRNA.
Table 4 HPV positivity, genotype, and HPV test by stage of triage and histology
HPV DNA 5-type-mRNA
HPVNeg. HPV 16 HPV 18 HPV other HPVNeg. HPV 16 HPV 18 HPV other
Stages of triage N % % % % N % % % %
At triagea 564 69.7 8.5 2.3 19.5 564 81.4 8.7 2.1 7.8
Recommended biopsyb 141 28.4 8.5 63.1 92 45.7 10.9 43.5
Had biopsyc 105 36.2 7.6 56.2 77 51.9 9.1 39.0
By histology N % % % N % % %
Normal/CIN1 67 26.9 7.5 65.7 47 44.7 8.5 46.8
CIN2 23 39.1 13.0 47.8 15 53.3 20.0 26.7
CIN3 14 71.4 0.0 28.6 14 71.4 0.0 28.6
Sq. cell carcinoma 1 0.0 0.0 100 1 0.0 0.0 100
HPV DNA other HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
5-type-mRNA other HPV type 31, 33, and 45
CIN cervical intraepitelial neoplasi
aThe Norwegian cervical cancer screening program recommended triage 6 to 12 months after the index ASC-US/LSIL
bWomen with either a positive HPV DNA or a positive HPV mRNA test are recommended biopsy
cIn total 141 women were recommended colposcopy by the DNA test, and 105 (74 %) met for biopsy. Out of the 92 women scheduled for biopsy by the 5-type
mRNA test, 77 (84 %) made a visit (p = 0.12)
Table 3 Test performance of HPV DNA test (N = 504) and
5-type-mRNA test (N = 536) in solved cases
Triage status CIN2+ CIN1- Total
HPV DNA positive 38 73 111a
HPV DNA negative 0 393 393
Total 38 466 504
Triage status CIN2+ CIN1- Total
HPV mRNA positive 30 47 77
HPV mRNA negative 8 451 459
Total 38 498 536
CIN2+ CIN2, CIN3, ACIS, and cervical cancer
CIN1- Normal and CIN1
aOf the 111 women with a positive HPV DNA test, six women had normal
cytology and a negative HPV DNA test at second follow-up and returned to
screening at 3-year interval
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Table 4 summarizes HPV positivity, genotype, stage of
triage and histology by HPV test. The DNA test detected
23 cases of CIN2, relative to 15 with the 5-type mRNA
test. There was concordance between tests in eight cases
of HPV16, three cases of HPV18, and three cases of
HPV other than 16 and 18. One CIN2 case testing
HPV16 in the DNA test tested HPV other than 16 and
18 in the 5-type mRNA test. The eight additional cases
of CIN2 detected by the DNA test were all negative for
HPV 16/18 and positive for other than 16 and 18: three
in the age group 25–34 years and five in the 35–69
group. All cases with CIN3 (n = 14) were concordant for
HPV type in both tests (n = 10 for HPV16, n = 4 for
HPV other than 16 or 18).
In total 89 % (504/564) of the DNA cases were solved
across the time frame of the study, relative to 95 % (536/
564) of the 5-type mRNA-tested cases (p < 0.01). The
cumulative proportions of cases solved within 12 and
36 months were significantly higher for 5-type mRNA-
tested subjects, 92 % (95 % CI: 90–94) and 96 % (95 %
CI: 94–98), than DNA-tested subjects, 85 % (95 % CI:
82–88) and 90 % (95 % CI: 87–93)).
The sensitivity among solved cases for CIN2+ of the
HPV DNA test was 100 % (38/38) relative to 79 % (30/
38, 95 % CI: 67–92) for the 5-type mRNA test. The cor-
responding estimates of specificity among solved cases
were 84 % (393/466, 95 % CI: 81–88), and 91 % (451/
498, 95 % CI: 88–93) (Table 3) (p < 0.01). In Tables 5, 6,
7 and 8 we provide data on triage cytology (ASC-US or
LSIL) by HPV test for CIN2+ and CIN3 + .
Discussion
Our study shows that the 5-type HPV mRNA test had
significantly lower positivity rate (19 %) than the 14-type
HPV DNA test (29 %), which led to a significantly higher
referral rate to colposcopy for the HPV DNA test. Both
tests diagnosed equal numbers of women with CIN3+,
whereas the DNA test detected eight more cases of
CIN2. All these CIN2 cases were of HPV types other
than 16/18 in both tests, and they were negative for
HPV mRNA 31, 33, and 45.
In agreement with other studies, the positivity rate of
the HPV DNA test in triage of ASC-US/LSIL is nearly
double compared to the 5-type HPV mRNA test (Table 9
[6, 7, 10–12, 16]). We found a 57 % higher referral rate
using HPV DNA versus 5-type mRNA while others have
reported a double referral rate ratio using HPV DNA
compared to 5-type mRNA [6, 7, 10].
Most studies report a higher sensitivity for CIN2+ and
CIN3+ using the HPV DNA test or 14-type HPV mRNA
test (Hologic APTIMA) compared to the 5-type HPV
mRNA test, whereas the specificity is significantly higher
for 5-type HPV mRNA compared to HPV DNA (or 14-
type HPV mRNA test) [6, 7, 16–18]. The higher specifi-
city reflects the higher positive predictive value (PPV)
for the HPV 5-type mRNA test relative to the HPV
DNA test (or 14-type HPV mRNA test).
The major difference in test performance between the
DNA and the 5-type mRNA test was HPV types other
than 16/18, which were in most cases HPV mRNA-
negative for 31/33/45. The choice of test is crucial to
Table 7 Test performance of HPV DNA test and 5-type HPV
mRNA test in repeated LSIL in solved cases versus CIN2+
Triage status CIN2+ CIN1- Total
HPV DNA positive 13 31 44
HPV DNA negative 0 5 5
Total 13 36 49
Triage status CIN2+ CIN1- Total
HPV mRNA positive 12 17 29
HPV mRNA negative 1 19 20
Total 13 46 49
CIN2+ CIN2, CIN3, ACIS, and cervical cancer
CIN1- Normal and CIN1
Table 6 Test performance of HPV DNA test and 5-type HPV
mRNA test in repeated ASC-US in solved cases versus CIN3+
Triage status CIN3+ CIN2- Total
HPV DNA positive 9 78 87
HPV DNA negative 0 28 28
Total 9 106 115
Triage status CIN3+ CIN2- Total
HPV mRNA positive 9 54 63
HPV mRNA negative 0 50 50
Total 9 104 113
CIN2+ CIN2, CIN3, ACIS, and cervical cancer
CIN1- Normal and CIN1
Table 5 Test performance of HPV DNA test and 5-type HPV
mRNA test in repeated ASC-US in solved cases versus CIN2+
Triage status CIN2+ CIN1- Total
HPV DNA positive 25 62 87
HPV DNA negative 0 28 28
Total 25 90 115
Triage status CIN2+ CIN1- Total
HPV mRNA positive 18 45 63
HPV mRNA negative 5 45 50
Total 23 90 113
CIN2+ CIN2, CIN3, ACIS, and cervical cancer
CIN1- Normal and CIN1
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avoid over-diagnosis in triage of women with minor
cytological lesions. Our data indicates that the difference
in sensitivity/loss of CIN2 may be attributed to HPV
types with a low oncogenic potential with slow progres-
sion into cancer. The next screening round will capture
these women for follow-up/treatment if there is any
progression. A triage HPV test with high specificity,
targeting the HPV types with the highest potential for
progression to cervical cancer, will reduce over-diagnosis
and overtreatment, as observed in this study. Over-
diagnosis is a cost-driver in unnecessary conizations and
may lead to an increased risk of premature births and
late abortions in subsequent pregnancies [19, 20] in this
young population.
In our study the 5-type HPV mRNA test detected the
same number of CIN3+, with a significant lower positiv-
ity rate and significant lower referral rate to colposcopy
than the HPV DNA test. The risk of cervical cancer in
women with ASC-US/LSIL is low and even lower if the
HPV mRNA test is negative [6, 16, 21]. In Europe,
HPV16 predominates in both CIN3 and cervical cancer.
Other HPV types have a slower progression into cancer
[22]. In countries with an organized cervical cancer
screening program the risk of development of cervical
cancer is higher for HPV types 16, 18, 31, 33 and 45
than for other HPV types [23]. These observations sup-
port the use of a specific HPV mRNA test detecting the
five main HPV types in triage of women with minor
cytological lesions.
In a meta-analysis of the accuracy of 5-type HPV
mRNA tests, the pooled sensitivity for CIN2+ of the 10
included studies was 75 % and 76 % for the triage of
ASC-US and LSIL, respectively [14]. It is well known
that many cervical lesions with moderate or severe dys-
plasia will regress spontaneously. Only 5 % of women
with CIN2 will develop cervical cancer without treat-
ment [24]. Only 31 % of colposcopically visible lesions
with CIN3 will progress to invasive cancer within
30 years [25]. About 40 % of CIN2 will regress within
two years, and the regression rate of CIN2 caused by
other HPV types than HPV type 16 is even higher [26].
It is probable that the 5-type HPV mRNA test in triage
of women with minor cervical lesions identifies the ma-
jority of the lesions that are destined to progress to can-
cer [27, 28]. When women with ASC-US/LSIL and a
negative 5-type mRNA test are returned to screening in
three years, we can reduce overtreatment of women with
CIN1-2 caused by HPV types with a low risk of progres-
sion [22, 23, 26, 29].
Table 9 Test-performance of the 5-type mRNA test and 13–14 types DNA tests in delayed triage and reflex testing of women with
minor cytological lesions and CIN3+ as outcome
Ref. Data
collection
























































































































































Sens Sensitivity; Spes. Specificity; PPV positive predictive value; NPV negative predictive value; NR Not reported; NRe Not relevant. All women had colposcopy
regardless of HPV result
aOnly solved cases are included in test-performance analysis
Table 8 Test performance of HPV DNA test and 5-type HPV
mRNA test in repeated LSIL in solved cases versus CIN3+
Triage status CIN3+ CIN2- Total
HPV DNA positive 6 38 44
HPV DNA negative 0 5 5
Total 6 43 49
Triage status CIN3+ CIN2- Total
HPV mRNA positive 6 23 29
HPV mRNA negative 0 20 20
Total 6 43 49
CIN2+ CIN2, CIN3, ACIS, and cervical cancer
CIN1- Normal and CIN1
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The experience in the Department of Pathology,
Ålesund Hospital, is that the 5-type HPV mRNA test
has a high specificity and a high positive predictive
value. This makes it useful for triage of women with
minor cervical lesions.
Conclusions
5-type HPV mRNA is more specific than HPV DNA in
triage of women with repeated ASC-US/LSIL. The referral
rate for colposcopy after repeated ASC-US/LSIL was 57 %
higher for DNA+ relative to mRNA+ cases, with the same
detection rate of CIN3+. It is important to consider the
trade-off between sensitivity and specificity of the diagnos-
tic test when designing screening algorithms.
Abbreviations
ASC-H, atypical squamous cells – cannot exclude HSIL; ASC-US, atypical
squamous cells of undetermined significance; CIN, cervical intraepithelial
neoplasia, also known as cervical dysplasia; CIN1, CIN2, CIN3, cervical
intraepithelial neoplasia grade 1, 2 or 3, also known as low grade, moderate
or severe cervical dysplasia; CIN2+, CIN2, CIN3, adenocarcinoma in situ (ACIS)
or cervical cancer DNA: Deoxyribonucleic acid; HPV, human papillomavirus;
HPV DNA test, cobas 4800 detects DNA from 14 high-risk HPV types (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) at clinically relevant infection
levels; HPV mRNA test, PreTect HPV-Proofer detects E6/E7 mRNA of 5 HPV
types (16, 18, 31, 33 and 45); HSIL, High grade squamous intraepithelial
lesion; LBC, liquid-based cytology; LSIL, low grade squamous intraepithelial
lesion; mRNA, messenger RNA; NPV, negative predictive value; Pap smear,
the Papanicolaou test, also known as Pap test, cervical smear or cervical





This research was supported by a grant from the Helse Møre og Romsdal
Trust. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Availability of data and materials
The data will not be made available in order to protect the participants identity.
Authors’ contributions
BW, SWS and FES participated in the design of the study. AG and HG
screened all the PAP-smears and performed HPV mRNA testing. BW reviewed
all the histological diagnosis. SWS and FES performed the statistical analysis.




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Regional Committee for Medical and Health Research Ethics, North
Norway, has approved the protocol as a quality assurance study in laboratory
work fulfilling the requirements for data protection procedures within the
department (2012/276/REK Nord). Norwegian regulations exempt quality
assurance studies from written informed consent from the patients (https://
lovdata.no/dokument/SF/forskrift/2000-12-15-1265).
Author details
1Department of Pathology, Ålesund Hospital, Møre and Romsdal Health
Trust, Ålesund, Norway. 2Department of Clinical Pathology, University
Hospital of North Norway, 9038 Tromsø, Norway. 3Research Group
Epidemiology of Chronic Diseases, Department of Community Medicine, UiT
The Arctic University of Norway, Tromsø, Norway.
Received: 8 February 2016 Accepted: 1 June 2016
References
1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al.
Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;12:2675–86.
2. Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV’s 16 and
18 infected cervical cancer: pathogenesis to prevention. Biomed
Pharmacother. 2015;70:103–10.
3. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
et al. Human papillomavirus genotype attribution in invasive cervical cancer:
a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.
4. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al.
American Cancer Society, American Society for Colposcopy and Cervical
Pathology, and American Society for Clinical Pathology screening guidelines
for the prevention and early detection of cervical cancer. Am J Clin Pathol.
2012;137:516–42.
5. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J.
Triage of women with equivocal or low-grade cervical cytology results: a
meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648–59.
6. Nygard M, Roysland K, Campbell S, Dillner J. Comparative effectiveness
study on human papillomavirus detection methods used in the cervical
cancer screening programme. BMJ Open. 2014;4:e003460.
7. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R,
Terrenato I, Ciccocioppo L, Frega A, Giorgi Rossi P. Sensitivity, specificity,
and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a
triage test for cervical cytology and HPV DNA test. J Clin Microbiol.
2011;49(7):2643–50. doi:10.1128/JCM.02570-10.
8. Koliopoulos G, Chrelias C, Pappas A, Makridima S, Kountouris E, Alepaki M,
Spathis A, Stathopoulou V, Panayiotides I, Panagopoulos P, Karakitsos P,
Kassanos D. The diagnostic accuracy of two methods for E6&7 mRNA
detection in women with minor cytological abnormalities. Acta Obstet
Gynecol Scand. 2012;91(7):794–801. doi:10.1111/j.1600-0412.2012.01414.x.
9. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES. Triage of women with
minor cervical lesions: data suggesting a “test and treat” approach for HPV
E6/E7 mRNA testing. PLoS One. 2010;5:e12724.
10. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. HPV
mRNA is more specific than HPV DNA in triage of women with minor
cervical lesions. PLoS One. 2014;9:e112934.
11. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al.
Comparison of predictors for high-grade cervical intraepithelial neoplasia
in women with abnormal smears. Cancer Epidemiol Biomarkers Prev.
2008;17:3033–42.
12. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, et al.
Comparison of seven tests for high-grade cervical intraepithelial neoplasia
in women with abnormal smears: the Predictors 2 study. J Clin Microbiol.
2012;50:1867–73.
13. Trope A, Sjoborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, et al.
Performance of human papillomavirus DNA and mRNA testing strategies for
women with and without cervical neoplasia. J Clin Microbiol. 2009;47:2458–64.
14. Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M. Triage of women
with minor abnormal cervical cytology: meta-analysis of the accuracy of an
assay targeting messenger ribonucleic acid of 5 high-risk human
papillomavirus types. Cancer Cytopathol. 2013;121:675–87.
15. Nygård JF, Skare GB, Thoresen SO. The cervical cancer screening
programme in Norway, 1992–2000: changes in Pap smear coverage and
incidence of cervical cancer. J Med Screen. 2002;9:86–91.
16. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al.
Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in
comparison with that of the Hybrid Capture 2 test for identification of
women at risk of cervical cancer. J Clin Microbiol. 2010;48:2779–85.
17. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence
regarding human papillomavirus testing in secondary prevention of cervical
cancer. Vaccine. 2012;30 Suppl 5:F88–99.
Westre et al. BMC Clinical Pathology  (2016) 16:9 Page 7 of 8
18. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The
APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women
with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic
accuracy. Int J Cancer. 2013;132:101–8.
19. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P,
et al. Perinatal mortality and other severe adverse pregnancy outcomes
associated with treatment of cervical intraepithelial neoplasia: meta-analysis.
BMJ. 2008;337:a1284. doi:10.1136/bmj.a1284.:a1284.
20. Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for
precancerous changes in the cervix: a systematic review and meta-analysis.
BJOG. 2011;118:1031–41.
21. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. HPV mRNA test in
women with minor cervical lesions: experience of the University Hospital of
North Norway. J Virol Methods. 2010;169:219–22.
22. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al.
Differences in human papillomavirus type distribution in high-grade cervical
intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer.
2013;132:854–67.
23. Powell NG, Hibbitts SJ, Boyde AM, Newcombe RG, Tristram AJ, Fiander AN.
The risk of cervical cancer associated with specific types of human
papillomavirus: a case–control study in a UK population. Int J Cancer.
2011;128:1676–82.
24. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical
review. Int J Gynecol Pathol. 1993;12:186–92.
25. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al.
Natural history of cervical neoplasia and risk of invasive cancer in women
with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet
Oncol. 2008;9:425–34.
26. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent
regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol.
2009;113:18–25.
27. Basu P, Roychowdhury S, Bafna UD, Chaudhury S, Kothari S, Sekhon R, et al.
Human papillomavirus genotype distribution in cervical cancer in India:
results from a multi-center study. Asian Pac J Cancer Prev. 2009;10:27–34.
28. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of
E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in
the majority of cervical carcinomas. J Clin Microbiol. 2006;44:1310–7.
29. Zappacosta R, Gatta DM, Marinucci P, Capanna S, Lattanzio G, Caraceni D,
et al. Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive
patients showing ASCUS and LSIL: clinical and economic implications in a
publicly financed healthcare system. Expert Rev Mol Diagn. 2015;15:1–14.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Westre et al. BMC Clinical Pathology  (2016) 16:9 Page 8 of 8
